AlloDirect raises pre-seed led by M25 to become the ordering layer for human tissue
What's the deal? AlloDirectDealroom has a profile for this one. Try Dealroom →, a direct sourcing platform for human tissue, has raised a pre-seed round led by Chicago-based M25Dealroom has a profile for this one. Try Dealroom →, with participation from angel investors. The Valparaiso, Indiana-based startup also named James A. Casavant, a 20-year healthcare supply chain software veteran, as chief technology officer.
What's the endgame? AlloDirect wants to be the ordering layer for human tissue. Facilities search one catalog of more than 24,000 allografts from six AATB-accredited tissue banks, place orders in a single workflow, and capture lot and UDI documentation at the point of order.
Orders route directly to the originating tissue bank for fulfillment. When a surgeon needs a graft that is not in the catalog, AlloDirect coordinates sourcing and delivery.
Why now? The company has been live since September 2025, processing orders for surgery centers and hospitals in Pennsylvania, Indiana, Texas, Oklahoma, and Florida.
The timing tracks a shift in where surgery happens. In its CY 2026 payment rule, the Centers for Medicare and Medicaid Services added more than 500 procedures to the ambulatory surgery center list and began a three-year phase-out of the inpatient-only list, starting with 285 largely musculoskeletal procedures.
More surgery that uses allograft tissue is moving to outpatient settings, which have the least procurement infrastructure in the chain.
What's the problem? Unlike most device distribution, allograft tissue ships straight from the tissue bank to the facility; intermediaries carry information, and carry it slowly. A facility asking what is available can wait days for an answer, one supplier at a time.
The gap runs both ways. Tissue banks process against forecasts, then distribute into a channel that returns little data on what facilities need. AlloDirect connects banks directly to buyers and gives them visibility into real demand.
What they said: "Every handoff between the tissue bank and the operating room adds time and cost, and none of them add anything to the graft," said founder and chief executive officer Rhett Barker, who spent six years in orthopedic sales at Zimmer Biomet.
Casavant, founding chief technology officer of a leading tissue and implant tracking SaaS platform, pointed to the core challenge. "The hard part of this category is the data," he said.
The signal: As payers push more musculoskeletal procedures into outpatient settings, the plumbing that moves donated tissue is being rebuilt for facilities that lack the procurement infrastructure larger hospitals rely on. AlloDirect is betting that the ordering layer — not the inventory — is where the value sits.
Read more: medium.com
Image credit: U.S. Naval Forces Central Command/U.S. Fifth Fleet
